TrialVaccine2023

Single Ad26.COV2.S booster dose following two doses of BBIBP-CorV vaccine against SARS-CoV-2 infection in adults: Day 28 results of a phase 1/2 open-label trial.

Sant Muangnoicharoen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.